170. Occipital horn syndrome Clinical trials / Disease details
Clinical trials : 2 / Drugs : 4 - (DrugBank : 3) / Drug target genes : 9 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04977388 (ClinicalTrials.gov) | July 12, 2021 | 9/7/2021 | NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome | Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial | Menkes Disease;Occipital Horn Syndrome | Drug: Droxidopa;Other: Placebo | Stephen G. Kaler, MD | NULL | Recruiting | 18 Years | 50 Years | All | 6 | Phase 1/Phase 2 | United States |